Leishmania amastigotes as targets for drug screening

Direct drug screening against the mammalian stage of Leishmania has been hampered by cost and the time consuming effort required to accomplish it. The ability to derive transgenic Leishmania expressing reporter genes opened up new possibilities for the development of drug screening tests. Further de...

Descripción completa

Detalles Bibliográficos
Autores principales: Monte-Alegre, Adriano, Ouaissi, Ali, Sereno, Denis
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2006
Materias:
Focus
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1635419/
https://www.ncbi.nlm.nih.gov/pubmed/17059597
http://dx.doi.org/10.1186/1475-9292-5-6
_version_ 1782130692392484864
author Monte-Alegre, Adriano
Ouaissi, Ali
Sereno, Denis
author_facet Monte-Alegre, Adriano
Ouaissi, Ali
Sereno, Denis
author_sort Monte-Alegre, Adriano
collection PubMed
description Direct drug screening against the mammalian stage of Leishmania has been hampered by cost and the time consuming effort required to accomplish it. The ability to derive transgenic Leishmania expressing reporter genes opened up new possibilities for the development of drug screening tests. Further developments to standardize and gather multiple informations could now be envisionned. We will discuss on such available methodologies that could improve sensitivity, reliability, versatility and the rapidity, of the screen based on intracellular model.
format Text
id pubmed-1635419
institution National Center for Biotechnology Information
language English
publishDate 2006
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-16354192006-11-09 Leishmania amastigotes as targets for drug screening Monte-Alegre, Adriano Ouaissi, Ali Sereno, Denis Kinetoplastid Biol Dis Focus Direct drug screening against the mammalian stage of Leishmania has been hampered by cost and the time consuming effort required to accomplish it. The ability to derive transgenic Leishmania expressing reporter genes opened up new possibilities for the development of drug screening tests. Further developments to standardize and gather multiple informations could now be envisionned. We will discuss on such available methodologies that could improve sensitivity, reliability, versatility and the rapidity, of the screen based on intracellular model. BioMed Central 2006-10-23 /pmc/articles/PMC1635419/ /pubmed/17059597 http://dx.doi.org/10.1186/1475-9292-5-6 Text en Copyright © 2006 Monte-Alegre et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Focus
Monte-Alegre, Adriano
Ouaissi, Ali
Sereno, Denis
Leishmania amastigotes as targets for drug screening
title Leishmania amastigotes as targets for drug screening
title_full Leishmania amastigotes as targets for drug screening
title_fullStr Leishmania amastigotes as targets for drug screening
title_full_unstemmed Leishmania amastigotes as targets for drug screening
title_short Leishmania amastigotes as targets for drug screening
title_sort leishmania amastigotes as targets for drug screening
topic Focus
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1635419/
https://www.ncbi.nlm.nih.gov/pubmed/17059597
http://dx.doi.org/10.1186/1475-9292-5-6
work_keys_str_mv AT montealegreadriano leishmaniaamastigotesastargetsfordrugscreening
AT ouaissiali leishmaniaamastigotesastargetsfordrugscreening
AT serenodenis leishmaniaamastigotesastargetsfordrugscreening

Ejemplares similares